PharmGen Science팜젠사이언스
004720 · KOSPI · ₩004720 · 팜젠사이언스
₩2,740▼ ₩10 (0.36%)End-of-day · Oct 28, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 65.2% | 64.5% | 63.1% | 58.7% | 53.9% | 55.3% |
| Operating margin | 2.4% | 3.5% | 6.2% | 5.5% | 5.0% | −4.5% |
| Net margin | −76.6% | −67.4% | 4.1% | 9.4% | 0.8% | −3.8% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +1.3% | +1.0% | +2.7% | +10.5% | +37.4% | — |
| Operating income growth | −30.1% | −43.8% | +16.6% | +22.1% | +251.7% | — |
| Net income growth | −15.2% | −1,766.2% | −55.3% | +1,178.2% | +129.1% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −93.8% | −87.5% | 6.0% | 15.7% | 1.5% | −5.4% |
| Return on assets | −70.8% | −58.5% | 3.5% | 8.7% | 0.7% | −2.6% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 31.5% | 33.6% | 68.7% | 69.3% | 95.8% | 110.2% |
| Net debt to equity | −14.3% | −11.6% | −0.1% | −0.3% | 22.5% | 17.2% |
| Current ratio | 333.0% | 285.2% | 169.2% | 150.8% | 103.4% | 108.7% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: PharmGen Science / 팜젠사이언스 / 004720 / KRX:004720
Source: KRX statistical information